Perceptive Advisors

Founded in 1999, Perceptive Advisors is a New York-based investment firm focused on the life sciences sector. It invests across various stages of company development, from seed to late-stage ventures and public equities, with a typical investment size ranging from $10 million to $200 million. The firm employs long/short equity strategies and conducts in-house research to identify promising opportunities in biotechnology, pharmaceuticals, life sciences, and healthcare services.

Michael Altman

Managing Director

Ben Askew Ph.D

Executive, Research and Development in Venture

Joseph Edelman

CEO and Founder

Hossein Ekrami Ph.D

Managing Director

Takeru Furuya Ph.D

Principal

Douglas Giordano

Managing Director

Ellen Hukkelhoven Ph.D

Managing Director

Harry Jenq

Vice President

Keyvan Mirsaeedi-Farahani MD

Vice President

Jeremiah Paskus

Vice President

Konstantin Poukalov

Managing Director and Perceptive Discovery Co-Head

Adam Stone

Chief Investment Officer and Head of Research

Craig Yeshion MD

Managing Director

Past deals in New Hampshire

Vapotherm

Acquisition in 2024
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

AgaMatrix

Debt Financing in 2019
AgaMatrix, Inc. is a company focused on developing and manufacturing advanced biosensors and blood glucose monitoring systems for individuals with diabetes. Established in 2001 and headquartered in Salem, New Hampshire, AgaMatrix offers an array of products designed to enhance diabetes care, including mobile blood glucose meters and data management software. One of its key innovations is the WaveSense technology, which personalizes testing by improving accuracy and correcting for potential errors arising from variations in blood samples and environmental conditions. The company also provides the AgaMatrix Diabetes Manager, which consolidates tracking of glucose, insulin, carbohydrates, and weight, as well as the Zero-Click system for streamlined data management. With a strong portfolio of over 160 patents covering its technologies, AgaMatrix partners with notable firms such as Biocorp Production and Sanofi to distribute its products through retail channels.

Vapotherm

Series D in 2018
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

Vapotherm

Series D in 2017
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

Vapotherm

Series C in 2015
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.